Business Context and Reporting Period
Oragenics, Inc. (OGEN) filed a Current Report on Form 8-K dated February 27, 2024, with the earliest event reported on that date. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock, which closed on March 1, 2024.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the transaction include:
- Gross Proceeds: $2.1 million from the sale of 1,400,000 shares.
- Public Offering Price: $1.50 per share.
- Underwriter Purchase Price: $1.395 per share.
- Over-Allotment Option: Underwriters granted an option to purchase up to 210,000 additional shares within 45 days.
- Representative's Warrants: Warrants issued to purchase up to 5% of the shares sold, exercisable 180 days after February 27, 2024, at an exercise price of $1.875 per share, expiring February 27, 2029.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is not a periodic financial report (e.g., 10-K or 10-Q).
Material Changes
The primary material change is the increase in outstanding common stock and the dilution resulting from the issuance of 1,400,000 shares plus potential over-allotment shares and warrants. The company received gross proceeds of $2.1 million, subject to deductions for underwriting discounts and offering expenses.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding expected net proceeds, which are subject to risks and uncertainties. Management disclaims any obligation to update these statements. Specific risks are referenced in the Company's Annual Report on Form 10-K (filed April 17, 2023), a Current Report on Form 8-K (filed January 16, 2024), and the prospectus supplement on Form 424B5 (filed February 29, 2024). No specific operational guidance or outlook was provided in this text.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Confirm whether the underwriters exercised the 210,000 share over-allotment option.
- Review the "Risk Factors" section in the Form 424B5 prospectus supplement for specific risks related to the offering.
- Check subsequent filings for the impact of this capital raise on the company's cash position and working capital.